Treatment of Sporadic MPNST with BRAF V600E Mutation

This protocol addresses a molecularly defined subgroup: sporadic malignant peripheral nerve sheath tumour (MPNST) in patients with a confirmed BRAF V600E mutation. The presence of this mutation distinguishes this subset and directly informs the treatment strategy.

Clinical scenario

Sporadic MPNST with a demonstrated BRAF V600E mutation. BRAF V600E mutations occur in a subset of sporadic MPNST cases and represent an actionable molecular target. This profile is distinct from NF1-associated MPNST and warrants a molecularly guided approach.

Treatment approach

In this molecularly selected population, treatment is directed at the identified BRAF pathway alteration using targeted inhibition. The full protocol — including the specific agent, clinical context, and decision framework — is available via the link below.

Treatment goal

Reduction in tumour size by 50%.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers16193266

BRAF p(V600E) mutations are found in a subset of sporadic MPNST — the case report literature describes a single patient with MPNST with demonstrated BRAF V600E mutation treated effectively with the BRAF inhibitor vemurafenib.

There was an isolated report by Kaplan who described a female MPNST patient with a BRAF mutation who received Vemurafenib for approximately 4 days, and following this, the tumour had shrunk by 50%.

View source ↗